AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06068673
Drug: Clindamycin 600 mg
RxNorm normalized name: clindamycin 600 MG
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin 900 - 1200 mg TWICE per day during 2 weeks period.
Trial: NCT06068673
Drug: standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard regimen
Trial: NCT06517667
Drug: Icross tear substitute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid substitute into each eye 3 times per day for 3 months.
Trial: NCT00018135
Drug: calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04770220
Drug: Experimental: ALZ-801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALZ-801 tablet 265 mg BID
Trial: NCT04770220
Drug: Placebo Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet BID
Trial: NCT05416580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
Trial: NCT04836273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal s.c. self-administration with placebo when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
Trial: NCT06501378
Drug: PD-1/PD-L1 inhibitor plus chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active brain metastases patients will receive PD-L1/PD-1 inhibitors and chemotherapy.
Trial: NCT00117104
Drug: Aranesp®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05424510
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of Ringer's Lactate
Trial: NCT05565729
Drug: LY3471851
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05565729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT06577233
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10cc of 0.9% normal saline will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery
Trial: NCT04751955
Drug: Olinvacimab added to Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Olinvacimab: IV weekly administration In phase lb, 12mg/kg and 16mg/kg weekly IV will be tested. In phase ll, the RP2D in phase lb will be used. Capecitabine: fixed dose as an oral administration, 1250mg/m2 BID on day 1 to 14 followed by 7 days off
Trial: NCT06480539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparator is a placebo, namely pure saline (NaCl 0.9%), which will be administered following the same regimen as the intervention.
Trial: NCT04167033
Drug: Hormone replacement therapy:effect on ventricular repolarization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy and QTc measurement
Trial: NCT05276375
Drug: Bronchipret
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchipret syrup (3x 5,4 ml daily) until day 14
Trial: NCT06510270
Drug: Loop diuretics
RxNorm normalized name: LOOP DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics (IV or orally) will be given to all patients in symptomatic heart failure group
Trial: NCT06510270
Drug: Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of associated co-morbidities will be given to both arms (group) such as anti-hypertensive (B blockers, ACIE, ARBS, CA channel blockers, Diuretics), oral hypoglycemic (Metformins, sulfonyl urea,.......)
Trial: NCT04959981
Drug: ERAS-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05221151
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
Trial: NCT06127693
Drug: Tetravalent Influenza Vaccine
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive the tetravalent influenza vaccine
Trial: NCT04867642
Drug: UCB0022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive doses of UCB0022 in a pre-specified sequence during the Treatment Period of Part A, B and C.
Trial: NCT04431258
Drug: ABTL0812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.
Trial: NCT04431258
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX will be dosed according to the standard following regimen:~* oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~* leucovorin 400 mg/m2, administered as 2-hour iv infusion~* irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~* fluorouracil 2400 mg/m2, administered as 46-hour iv infusionevery 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.
Trial: NCT04431258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered daily at the same regim as ABTL0812. Placebo will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued, if the patient is in response or stable disease.
Trial: NCT05622474
Drug: Induction chemotherapy plus Concurrent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy: TP( Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles) OR GP (Gemcitabine 1000mg/m2，D1,D8 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles）~Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.
Trial: NCT06170476
Drug: HSK21542-60μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Trial: NCT06170476
Drug: HSK21542-120μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Trial: NCT06170476
Drug: HSK21542-180μg
RxNorm normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Trial: NCT06170476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Trial: NCT05312463
Drug: Tongjiang granule simulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongjiang granule simulant,1 bag / time, 3 times / day.
Trial: NCT05170048
Drug: EG-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigation drug, EG-301 Tablets 150mg, is for oral use.
Trial: NCT03533153
Drug: Conventional drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
Trial: NCT06475755
Drug: Immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant：Tislelizumab 200mg iv，d1，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
Trial: NCT04974996
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) infusion
Trial: NCT04974996
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT05648201
Drug: Biktarvy 50/200/25 Tab
RxNorm normalized name: BIKTARVY 50/200/25 TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single dose of 50/200/25 taken orally
Trial: NCT05836350
Drug: 4.8 g/m^2/day NaPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
Trial: NCT05836350
Drug: 4.8 g/m^2/day placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) or placebo per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
Trial: NCT06218940
Drug: HY1272
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily
Trial: NCT06032195
Drug: Custodiol-N
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heart will preserved in and will be treated with Custodiol-N solution
Trial: NCT06032195
Drug: Custodiol
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heart will preserved in and will be treated with Custodiol solution
Trial: NCT05550142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution
Trial: NCT05136885
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration: Infusion Dose: equivalent weight-based volume as described for trehalose
Trial: NCT05020665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally as tablets
Trial: NCT05020665
Drug: Anthracycline
RxNorm normalized name: Anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either daunorubicin or idarubicin was administered via slow intravenous (IV) push
Trial: NCT05342623
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken orally 1 time/day
Trial: NCT06363370
Drug: Inhalation Solution Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Inhalation Solution Placebo
Trial: NCT04229095
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose administration of placebo given on an inpatient clinical research unit
Trial: NCT05322941
Drug: AEF0117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEF0117 (1.0, 0.3, and 0.1 mg) capsules
Trial: NCT05322941
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil capsule manufactured to mimic AEF0117 capsule
Trial: NCT06683300
Drug: DAPT for 3 months after vertebral artery stenting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After implantation of a drug-eluting stent in the vertebral artery, dual antiplatelet therapy (DAPT) were administered for 3 months. The types of antiplatelet medications are not limited, with the standard regimen consisting of aspirin 100 mg once daily combined with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily. Additional antiplatelet agents such as indobufen may also be considered acceptable.
Trial: NCT05207514
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
Trial: NCT05207514
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
Trial: NCT06332079
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT06143241
Drug: Antiepileptic medication
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They will continue their antiepileptic medication prescribed by their doctor.
Trial: NCT05800938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets were given twice daily for 4 weeks
Trial: NCT06383897
Drug: HS-10398 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14
Trial: NCT05354778
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Corticosteroid
Trial: NCT05389930
Drug: Alcohol placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beverage contains only juice and a negligible trace of alcohol for masking
Trial: NCT03674320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Injection (saline) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
Trial: NCT05361655
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor therapy
Trial: NCT06482190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo across Part 1 and Part 2 of the study.
Trial: NCT05269446
Drug: TSPO injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 before a whole-body scan by uExplorer
Trial: NCT05138770
Drug: VC005 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 Tablets 1、5、10、25、50、100mg single dose
Trial: NCT05138770
Drug: VC005 Tablets Placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 Tablets Placebo 1、5、10、25、50、100mg single dose
Trial: NCT05138770
Drug: VC005 Tablets food effects group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 Tablets qd per period, for two periods
Trial: NCT05131373
Drug: ORG101 - Experimental 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals
Trial: NCT05131373
Drug: ORG101PL - Placebo 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals
Trial: NCT05091541
Drug: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
Trial: NCT06221241
Drug: JMKX000623
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets for oral administration.
Trial: NCT06221241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched to JMKX000623 and Pregabalin
Trial: NCT05101746
Drug: Nitric Oxide (NO) 20 part per million (ppm)
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide will be mixed into the gas flow of the cardiopulmonary bypass (CPB) oxygenator, which will be kept at 1-3 L/min to allow for the desired NO delivery rate. NO levels will be maintained at 20ppm using a NO delivery system (INOmax, Mallinckrodt).
Trial: NCT03991299
Drug: Botox 200 UNT Injection
RxNorm normalized name: Botox 200 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox will be injected into duodenums of subjects by endoscopy.
Trial: NCT04666701
Drug: Escócia association
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escócia association tablet
Trial: NCT05872555
Drug: Psychiatric Drugs
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving any Antipsychotic, Benzodiazepine, antidepressant, mood stabilizer
Trial: NCT06097923
Drug: Active fluid management with BIA monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants in active fluid management with BIA monitoring arm received fluid supplementation targeting specific range of ECW ratio by BIA (0.390-0.406). If a patient with dehydrated status indicated by the ECW ratio was less than 0.390, a bolus infusion was performed using 250ml of crystalloid fluid (PlasmaLyte). If a patient with overhydrated status indicated by the ECW ratio was more than 0.406, 10mg of furosemide was administered. Changes in the ECW ratio were measured at one hour after initial intervention for fluid adjustment, and these processes continued until the ECW ratio was within the normal range (0.390-0.406).
Trial: NCT06097923
Drug: Conventional fluid management without BIA monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants in conventional fluid management without BIA monitoring arm underwent conventional fluid management without specific targets of ECW ratio by BIA.
Trial: NCT04762979
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitor, administered per standard of care
Trial: NCT04691843
Drug: Iron Sulfate
RxNorm normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early, high dose, iron supplementation
Trial: NCT04679350
Drug: hzVSF-v13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
Trial: NCT06004921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT06684054
Drug: docetaxel, anthracycline, cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Participants were required to receive 6 cycles of TEC/TAC neoadjuvant chemotherapy, and radical mastectomy was required after chemotherapy.~2. 5ml peripheral venous blood was collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.~3. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.
Trial: NCT05540912
Drug: D064+D701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference
Trial: NCT05540912
Drug: CKD-828 Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test 2
Trial: NCT06244550
Drug: Ganwei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT06244550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules
Trial: NCT06579274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous injection can be administered quickly and directly into a vein or through an intravenous infusion set.
Trial: NCT06389305
Drug: CIK cell
RxNorm normalized name: Testone CIK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: autologous or allogeneic cytokine-induced killer (CIK) cells
Trial: NCT05654870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching valbenazine
Trial: NCT06684158
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LV：200 mg/m2 iv gtt d1，every 2 weeks (Q2W)
Trial: NCT04545151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily
Trial: NCT06578286
Drug: ARX788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARX788，1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle